Belhaven BioPharma Intranasal Epinephrine Delivery Device Patent
Summary
Belhaven BioPharma Inc. received US Patent 12605517B1 on April 21, 2026, titled 'Compositions, devices, and methods for intranasal delivery of dry powder epinephrine.' The patent contains 15 claims and names Scott Lyman and Brian Taubenheim as inventors. The patented compositions include epinephrine with a stabilizing agent (citric acid or salt) and carrier for intranasal dry powder delivery. The patent is assigned under CPC classifications A61M 15/08, A61M 11/003, A61K 9/0043, and A61K 31/137. Belhaven BioPharma now holds enforceable intellectual property rights to this intranasal epinephrine formulation in the United States. Competitors developing similar intranasal epinephrine delivery systems for anaphylaxis or respiratory conditions should conduct Freedom to Operate analyses to assess potential infringement exposure.
“Intranasal dry powder epinephrine compositions are described herein.”
About this source
GovPing monitors USPTO Patent Grants - Medical Devices (A61M) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 39 changes logged to date.
What changed
The USPTO granted Patent 12605517B1 to Belhaven BioPharma Inc. on April 21, 2026, covering intranasal dry powder epinephrine compositions with citric acid or salts as stabilizing agents and a carrier. The patent claims priority to Application 19242180 filed June 18, 2025. The invention is classified under A61M 15/08, A61M 11/003, A61M 11/007, A61K 9/0043, A61K 31/137, and A61K 47/12.
Belhaven BioPharma now holds exclusive rights to manufacture and commercialize this intranasal epinephrine formulation in the United States. Competitors developing intranasal epinephrine products for anaphylaxis, bronchospasms, or other indicated conditions should review this patent for potential Freedom to Operate concerns. Licensing negotiations with Belhaven BioPharma may be required for companies seeking to enter this therapeutic space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions, devices, and methods for intranasal delivery of dry powder epinephrine
Grant US12605517B1 Kind: B1 Apr 21, 2026
Assignee
Belhaven BioPharma Inc.
Inventors
Scott Lyman, Brian Taubenheim
Abstract
Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).
CPC Classifications
A61M 15/08 A61M 11/003 A61M 11/007 A61K 9/0043 A61K 31/137 A61K 47/12
Filing Date
2025-06-18
Application No.
19242180
Claims
15
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.